103 results about "Diabetic ulcer" patented technology

A method of noncontact imaging for performing qualitative and quantitative analysis of wounds includes the step of performing structured illumination of surface and subsurface tissue by both diffuse optical tomography and rapid, wide-field quantitative mapping of tissue optical properties within a single measurement platform. Structured illumination of a skin flap is performed to monitor a burn wound, a diabetic ulcer, a decubitis ulcer, a peripheral vascular disease, a skin graft, and / or tissue response to photomodulation. Quantitative imaging of optical properties is performed of superficial (0-5 mm depth) tissues in vivo. The step of quantitative imaging of optical properties of superficial (0-5 mm depth) tissues in vivo comprises pixel-by-pixel demodulating and diffusion-model fitting or model-based analysis of spatial frequency data to extract the local absorption and reduced scattering optical coefficients.

The present invention relates to a device consisting of cross-linked nanofibrillary fibrin supported on and rooted to a microporous nonwoven fabric consisting of a biocompatible synthetic polymer material. An active ingredient is advantageously dispersed in the fibrin layer. The fibrin layer does not have a haemostatic function, but is suitable for retaining the active ingredient and releasing it with controlled kinetics. The device forming the object of the invention, preferably in the form of patches, is useful for in vitro cell cultures or for treating tissues damaged by wounds or necrosis, such as cardiac walls bearing the sequelae of infarction, or a tissue damaged by a diabetic ulcer. The patch according to the invention can be manufactured by inducing the polymerisation of the fibrin, under suitable conditions, directly on the support layer, which is suitably impregnated with thrombin (at least in a superficial portion of its thickness), and which has been conveniently prepared by means of a spray phase-inversion technique.

The present invention provides a multimeric form of a Tie 2 binding peptide monomer, wherein the multimeric form has Tie 2 agonist activity. The multimeric form, preferably a tetramer, stimulates angiogenesis and promotes wound healing. The present invention also features pharmaceutical compositions comprising the multimeric Tie 2 agonists, including those suitable for topical or systemic administration. Methods of using the multimeric Tie 2 agonists of the invention for stimulating angiogenesis and for promoting healing of wounds, such as diabetic ulcers or skin grafts, are also provided.

Compositions and methods are provided for the treatment of chronic wounds, including, without limitation, pressure ulcers and diabetic ulcers, by transdermal delivery of an agent that increases activity of HIF-1α in the wound. Agents that increase HIF-1α activity include, without limitation, agents that stabilize HIF-1α, e.g. deferoxamine, deferiprone, deferasirox, etc.; agents that upregulate expression of HIF-1α, e.g. dimethyloxalylglycine, etc., HIF-1α polypeptide or coding sequences; and combinations thereof. Such agents may be referred to herein as HIF-1α potentiating agents.

The invention relates to a biological activity mineral substance material and application of biological activity mineral substance material to soft tissue anabrosis and long-time erosion wound cell regeneration and melanoma restraining. The application is mainly achieved by wrapping biological activity mineral substance material powder with the particle size smaller than 10 micrometers by medical glycerinum into gel and coating the surfaces of wounds with the gel. The biological activity mineral substance material is prepared from, by mass, 36% of SiO2, 5% of Na2O, 20% of CaO, 15% of P2O5, 5% of medical carboxymehyl chitosan, 5% of medical sodium hyaluronate, 10% of PEG, 2% of allantoin and 2% of tocopheryl acetate. The biological activity mineral substance material is particularly suitable for treating soft tissue anabrosis such as diabetic ulcer, dental ulcer, cervical erosion, fat liquefaction wounds, bedsores, sinus tracts, venereal disease ulcer, hemorrhoids and wounds.

The invention relates to application of sodium alginate oligose and a derivative to treatment of inflammations. The sodium alginate oligose and the derivative of the sodium alginate oligose are particularly mannuronic acid oligose or mannuronic acid oligose with a carboxyl at a 1-position of a reducing end and the derivative or a pharmaceutically acceptable salt, formed by connecting a beta-D-mannuronic acid through a 1,4-glucosidic bond. The inflammations are particularly a vascular inflammation, a neuroinflammation, a nervous centralis inflammation, arthritis, Crohn's disease, ulcerative colitis, inflammatory diabetic ulcer, psoriasis, atopic dermatitis and eczema.

Compositions and methods are provided for the prevention and treatment of chronic wounds, including, without limitation, pressure ulcers and diabetic ulcers, by transdermal delivery of an agent that increases activity of HIF-1α in the wound.

The invention relates to a wound dressing comprising a microbial-derived cellulose for treatment of specific types of chronic wounds, including pressure sores, venous and diabetic ulcers. The wound dressing is capable of donating liquid to dry substrates is also capable of absorbing exudating wounds.

The invention relates to a controlled-release antibacterial dressing and a preparation method thereof and particularly discloses a compound. The compound contains a dressing carrier and microspheres loaded to the dressing carrier. The invention further discloses a composition, a dressing as well as a preparation method and use of the dressing. According to the composition and the dressing, the pharmaceutical burst release phenomenon of a common antibacterial dressing can be effectively improved, and the growth and reproduction of germs such as escherichia coli, staphylococcus aureus, pseudomonas aeruginosa and Candida albicans can be steadily inhibited for a long time. The controlled-release antibacterial dressing provided by the invention is applicable to the treatment of operation cuts,wounds, burns, donor sites, pressure sores, diabetic ulcer and other wound surfaces.

Compositions for the treatment of wounds and / or scars are described herein. The compositions contain between 1 and up to 30% by weight, more preferably between 1 and 20%, most preferably between about 5 and 10% by weight particles, such as titanium dioxide or a similar material in a pharmaceutically acceptable base or carrier, such as petrolatum. The compositions are less greasy than petrolatum alone, and thus are more aesthetically pleasing. The compositions exhibit occlusive properties comparable to petrolatum. The compositions are absorbed into the skin, unlike petrolatum, and exhibit significant wound healing characteristics not observed with petrolatum alone. In one embodiment, the pharmaceutically acceptable base is petrolatum and the particles are titanium dioxide. The compositions can be used to treat complex, hard to heal wounds, such as diabetic ulcers; pressure sores, such as bed sores; lacerations; bite wounds; burns; penetrating wounds; surgical wounds, etc. The composition can also be used to promote normal healing of scar tissue. The compositions can also be used for the topical delivery of one or more active agent. The compositions can be used to reduce fine lines and wrinkles, and to rehydrate skin or to treat dry skin.

The present invention is directed to a specialized method of treating a severe diabetic ulcer that penetrates the subcutaneous fat layer of a patient. The method comprises the steps of: administering a treatment session to a diabetic patient having a severe diabetic ulcer, the treatment session comprising at least three pulsed electromagnetic fields (PEMF) applications, PEMF applications 1, 2, and 3, and at least two intermittent compression therapy (ICT) applications. The PEMF application and ICT therapy settings address specific factors that are necessary to induce healing of the diabetic ulcer and prevent amputation. In a preferred embodiment, the treatment session further comprises the step of applying a dressing having a silver and / or honey anti-infection composition thereon to the ulcer area to impede microbial growth in the ulcer area. In another embodiment, the method includes the step of applying ultrasound to the ulcer area for a time sufficient to inhibit microbial growth.

Disclosed are compositions and methods for promoting or accelerating wound healing and preventing, treating, or reducing symptoms associated with wounds or wounding disorders such as diabetic ulcers and burns. In one embodiment, the method includes administering a therapeutically effective amount of a nucleic acid encoding at least one morphogen, or an effective fragment thereof. Preferred morphogens include the human Sonic Hedghog (Shh), human Desert Hedgehog (Dhh), and human Indian Hedgehog (Ihh) proteins. The methods can be used alone or in combination with other methods involving administration of an angiogenic protein, a hematopoietic protein, or cells such as endothelial cells or endothelial precursor cells.

Disclosed is a method of promoting healing of a chronic dermal skin ulcer, such as a diabetic ulcer, on a subject. The method comprises the step of contacting the chronic dermal skin ulcer with an effective amount of an agonist of the non-proteolytically activated thrombin receptor.

A novel polypeptide, and an antibacterial agent, antifungal agent and / or antiseptic containing as an effective ingredient the polypeptide are disclosed. The polypeptide of this invention has an amino acid sequence shown in SEQ ID NOs:1 to 12 and 13 to 31. This antibacterial agent, antifungal agent and / or antiseptic is useful for the prevention, amelioration or treatment of diseases such as burn, decubitus, wound, skin ulcer, leg ulcer, diabetic ulcer, occlusive arterial disease and arteriosclerosis obliterans, cellulitis, acute lymphangitis, lymphadenitis, erysipelas, skin abscess, necrotizing subcutaneous infection, staphylococcal scalded skin syndrome (SSSS), folliculitis, facial furuncle, suppurative hidradenitis, carbuncle, infectious paronychia, erythrasma and severe infection (sepsis).

A system and method for facilitating the healing of a skin ulcer, such as a diabetic ulcer, on a treatment region of a body. Ultrasound waves are transmitted to the treatment region. Interferential electrical stimulation is applied to the treatment region, simultaneously with the ultrasound transmission. The treatment region may be massaged with a massaging device during the treatment session. A gel may be applied onto the treatment region to facilitate the ultrasound transmission and electrical stimulation. A measurement system may be used to obtain accurate measurements of the skin ulcer, to provide a quantitative determination of the healing progression.

The invention discloses a muramidase hydrolase external sterile cream for treating skin ulcer and a preparation method thereof. The muramidase hydrolase external sterile cream is prepared from the following raw materials of: muramidase hydrolase, Span, poloxamer, Tween, sorbierite, sodium dihydrogen phosphate, ethylparaben, liquid paraffin, glycerin monostearate, cetyl alcohol, stearyl alcohol, albolene and sterile water. The invention also provides a preparation method for the muramidase hydrolase external sterile cream. The preparation method comprises the following steps of: dissolving; performing high temperature sterilization; filtering and removing bacteria by using a filter membrane; homogenizing at a low speed; homogenizing at a high speed; stirring; reducing temperature; and performing sterile filling. The muramidase hydrolase external sterile cream is used for treating the skin ulcer including bedsore, burn ulcer, calf ulcer, post-zoster ulcer, diabetic ulcer and postoperative ulcer in a transdermal administration form.

The present invention relates to a method of determining the microbial bioburden in a wound (in particular a diabetic ulcer) in a test subject, the method comprising the step of measuring the level of a cytokine in a wound sample, wherein a cytokine level lower than a reference level indicates a significant microbial bioburden in the wound (or a cytokine level higher than a reference level indicates an insignificant microbial bioburden in the wound). The invention provides methods of diagnosis, prognosis and treatment of wound infection, and devices and kits for use in such methods.

The invention relates to a separation and storage method of a pouch fat interstitial cell, which comprises the following steps of: cutting to obtain a pouch fat tissue by adopting a surgical knife, extracting an interstitial tissue of the pouch fat tissue and separating the cell by using an adherent method. The culture and amplification method of the pouch fat interstitial cell comprises the following steps of: carrying out large-scale tissue culture by adopting a paper carrier technology, freezing and storing by using a definite and non-specific genetic component and preserving the cell for a long time. Through the separation and storage method, the pouch interstitial cell can be extracted, massively cultured and preserved for a long time; and the cultured interstitial cell can be used for promoting the healing of skin wound, the healing of diabetic ulcer, the repair of myocardial injury and the repair of hepatic injury.

The invention relates to methods and compositions for improving wound healing and in particular for preventing scar formation and thus loss of function that can occur in injured tissues during the natural wound healing process. Particularly, although by no means exclusively, the invention relates to the healing of chronic wounds such as diabetic ulcers.

This invention relates to methods for treating bacterial infection, which methods find utility in the treatment of, for example, infected ulcers, optionally infected diabetic ulcers. In particular, this invention relates to treating bacterial infection, for example, infected diabetic ulcers by topical administration of at least one aminoglycoside antibiotic at the site of infection, in combination with at least one antibacterial agent, which antibacterial agent is administered remote from the site of infection, preferably administered systemically. In a particular embodiment, the present invention relates to a composition for use in treating bacterial infection, the composition comprising gentamicin sulphate (a water-soluble broad-spectrum aminoglycoside antibiotic) uniformly dispersed in a type-I collagen matrix; in combination with at least one systemically-administered antibacterial agent. The present invention provides bactericidal activity against most strains of aerobic gram-negative and gram-positive and facultative anaerobic gram-negative pathogens, including methicillin-resistant Staphylococcus aureus.

The invention relates to an alprostadil nanoparticle preparation and a preparation method thereof. The preparation is essentially used for transdermal administration and used for treating diseases such as diabetic ulcer, ischemia of extremity end, burn and the like, and belongs to the technical field of medicine. The preparation consists of the raw materials by the following weight ratio that alprostadil:lipid component: emulsifier: excipient matrix: water is 0.01-0.1:0.5-10:0.5-5:550-950:5. The alprostadil nanoparticle preparation has the advantages of overcoming the chemical and physiological instability of the alprostadil, strengthening in vitro stability, reducing degradation of the alprostadil caused by inactivation effect of in vivo pulmonary circulation, enhancing concentration of the preparation on the local affected parts, being more easy to aggregate at the affected part, sustained release and long effect, and reducing irritation of the preparation.

Disclosed is a method of promoting healing of a chronic dermal ulcer, such as a diabetic ulcer, in a subject. The method comprises administering to the subject a combination one or more agonists of the non-proteolytically activated thrombin receptor and one or more angiogenic growth factors.

The method of treating delayed healing of a wound associated with diabetes includes administering to the wound a composition comprising an anti-senescence compound and a pharmaceutically acceptable carrier. The anti-senescence compound may be 18α-Glycyrrhetinic acid, a Caveolin-1 (Cav-1) inhibitory compound, or a Polymerase I Transcript Release Factor (PTRF-1) inhibitory compound. The anti-senescence compound may be effective in preventing and / or reversing premature cellular senescence. The anti-senescence compound may be effective in promoting healing of a wound, e.g., delayed or incompletely healed wound. The anti-senescence compound may be effective in promoting healing of a delayed healing wound or chronic wound of a diabetic patient, such as a diabetic ulcer or venous ulcer.

The present invention provides a bioactive polysaccharide dressing for wound repair, particularly chronic wound repair, and a preparation method and an application thereof. The preparation method of the dressing of the invention is simple and easy, and the prepared biological dressing has good adhesion, safety, non-toxicity and convenient application. The bioactive fucoidan sulfate hydrogel dressing has the effect of stopping bleeding, moisturizing and promoting chronic wound healing while isolating the wound surface, and has good permeability. The dressing is particularly suitable for the treatment and nursing of chronic refractory wounds which are widely existed in clinical application, especially diabetic ulcers.